Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Colorectal Neoplasms

  Free Subscription


Articles published in Oncology

Retrieve available abstracts of 21 articles:
HTML format
Text format



Single Articles


    May 2017
  1. LARSEN FO, Markussen A, Nielsen D, Colville-Ebeling B, et al
    Dual Inhibition of EGFR and VEGF in Heavily Pretreated Patients with Metastatic Colorectal Cancer.
    Oncology. 2017 May 23. doi: 10.1159/000475818.
    PubMed     Text format     Abstract available


    April 2017
  2. LIM KH, Lee HY, Park SB, Song SY, et al
    Feasibility of Modified FOLFOX in Elderly Patients Aged >/=80 Years with Metastatic Gastric Cancer or Colorectal Cancer.
    Oncology. 2017 Apr 27. doi: 10.1159/000471767.
    PubMed     Text format     Abstract available


  3. TSUKAMOTO M, Iinuma H, Yagi T, Matsuda K, et al
    Circulating Exosomal MicroRNA-21 as a Biomarker in Each Tumor Stage of Colorectal Cancer.
    Oncology. 2017;92.
    PubMed     Text format     Abstract available


    February 2017
  4. SAITO G, Sadahiro S, Kamata H, Miyakita H, et al
    Monitoring of Serum Carcinoembryonic Antigen Levels after Curative Resection of Colon Cancer: Cutoff Values Determined according to Preoperative Levels Enhance the Diagnostic Accuracy for Recurrence.
    Oncology. 2017 Feb 9. doi: 10.1159/000456075.
    PubMed     Text format     Abstract available


  5. HASEGAWA H, Taniguchi H, Mitani S, Masuishi T, et al
    Efficacy of Second-Line Bevacizumab-Containing Chemotherapy for Patients with Metastatic Colorectal Cancer following First-Line Treatment with an Anti-Epidermal Growth Factor Receptor Antibody.
    Oncology. 2017 Feb 1. doi: 10.1159/000453336.
    PubMed     Text format     Abstract available


    January 2017
  6. NOZAWA H, Ishihara S, Kawai K, Hata K, et al
    Characterization of Conversion Chemotherapy for Secondary Surgical Resection in Colorectal Cancer Patients with Lung Metastases.
    Oncology. 2017;92:135-141.
    PubMed     Text format     Abstract available


  7. KASAGI Y, Oki E, Ando K, Ito S, et al
    The Expression of CCAT2, a Novel Long Noncoding RNA Transcript, and rs6983267 Single-Nucleotide Polymorphism Genotypes in Colorectal Cancers.
    Oncology. 2017;92:48-54.
    PubMed     Text format     Abstract available


  8. KIM DW, Byer J, Kothari N, Mahipal A, et al
    EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.
    Oncology. 2017;92:190-196.
    PubMed     Text format     Abstract available


    December 2016
  9. YANG CA, Huang HY, Chang YS, Lin CL, et al
    DNA-Sensing and Nuclease Gene Expressions as Markers for Colorectal Cancer Progression.
    Oncology. 2016;92.
    PubMed     Text format     Abstract available


  10. ALDIAB A, Al Khayal KA, Al Obaid OA, Alsheikh A, et al
    Clinicopathological Features and Predictive Factors for Colorectal Cancer Outcome in the Kingdom of Saudi Arabia.
    Oncology. 2016.
    PubMed     Text format     Abstract available


    October 2016
  11. ABE S, Kawai K, Ishihara S, Nozawa H, et al
    Prognostic Value of Pre- and Postoperative Anti-p53 Antibody Levels in Colorectal Cancer Patients: A Retrospective Study.
    Oncology. 2016.
    PubMed     Text format     Abstract available


    August 2016
  12. PAOLICCHI E, Vivaldi C, De Gregorio V, Crea F, et al
    Topoisomerase 1 Promoter Variants and Benefit from Irinotecan in Metastatic Colorectal Cancer Patients.
    Oncology. 2016.
    PubMed     Text format     Abstract available


  13. SUGITA K, Kawakami K, Yokokawa T, Sugisaki T, et al
    Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study.
    Oncology. 2016;91:224-230.
    PubMed     Text format     Abstract available


    July 2016
  14. AMAKI-TAKAO M, Yamaguchi T, Natsume S, Iijima T, et al
    Colorectal Cancer with BRAF D594G Mutation Is Not Associated with Microsatellite Instability or Poor Prognosis.
    Oncology. 2016.
    PubMed     Text format     Abstract available


  15. NOZAWA H, Ishihara S, Kawai K, Murono K, et al
    Paradoxical Reductions in Serum Anti-p53 Autoantibody Levels by Chemotherapy in Unresectable Colorectal Cancer: An Observational Study.
    Oncology. 2016.
    PubMed     Text format     Abstract available


    June 2016
  16. SAITO G, Sadahiro S, Okada K, Tanaka A, et al
    Relation between Carcinoembryonic Antigen Levels in Colon Cancer Tissue and Serum Carcinoembryonic Antigen Levels at Initial Surgery and Recurrence.
    Oncology. 2016.
    PubMed     Text format     Abstract available


    May 2016
  17. YOSHIDA M, Takagane A, Miyake Y, Shimada K, et al
    A Phase II Study of Third-Line Combination Chemotherapy with Bevacizumab Plus S-1 for Metastatic Colorectal Cancer with Mutated KRAS (SAVIOR Study).
    Oncology. 2016.
    PubMed     Text format     Abstract available


    January 2016
  18. CHOI EJ, Yoo NJ, Kim MS, An CH, et al
    Putative Tumor Suppressor Genes EGR1 and BRSK1 Are Mutated in Gastric and Colorectal Cancers.
    Oncology. 2016;91:289-294.
    PubMed     Text format     Abstract available


  19. KOHLER C, Marnitz S, Biel P, Cordes T, et al
    Successful Delivery in a 39-Year-Old Patient with Anal Cancer after Fertility-Preserving Surgery Followed by Primary Chemoradiation and Low Anti-Mullerian Hormone Level.
    Oncology. 2016;91:295-298.
    PubMed     Text format     Abstract available


  20. RUBIO I, Ibanez-Feijoo E, Andres L, Aguirre E, et al
    Analysis of Lynch Syndrome Mismatch Repair Genes in Women with Endometrial Cancer.
    Oncology. 2016;91:171-6.
    PubMed     Text format     Abstract available


  21. KHAN AA, Akritidis G, Pring T, Alagarathnam S, et al
    The Neutrophil-to-Lymphocyte Ratio as a Marker of Lymph Node Status in Patients with Rectal Cancer.
    Oncology. 2016;91:69-77.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Colorectal Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: